Glivec International Patient Assistance Program (GIPAP)
Active Since: 2001
Contributing to SDGs…
A direct-to-patient model, in response to lower-income countries facing access and reimbursement challenges for cancer treatments, and a lack of patient support and oncology infrastructures.
Accepts and reviews applications for GIPAP; Sole responsibility for processing and assessing patients’ eligibility for GIPAP; Follows up on patients’ applications and re-evaluations; Provides emotional support, information, and referral assistance to patients ; Provides information concerning adverse events to Novartis for reporting to Health Authorities; Identifying and qualifying leading medical centers, charity organizations, and/or physicians, as required
- Ensure access to Glivec and select other Novartis Oncology Products for patients in need.
- Guarantee effective management of the program.
- Support the drug distribution and tracking process.
A direct-to-patient model, GIPAP opened in 2002 in response to lower-income countries facing access and reimbursement challenges for cancer treatments, and a lack of patient support and oncology infrastructures. GIPAP initially provided Glivec® (imatinib) at no cost to patients diagnosed with chronic myeloid leukemia (CML) with no access to reimbursement or funding mechanisms, and to those unable to pay for the medication in these countries. In GIPAP, Novartis managed the supply chain and direct interaction with local stakeholders (e.g., physicians, treatment centers, NGOs, private companies and governments) while The Max Foundation provided patients psychosocial support and education. Since 2002, it has operated in over 75 countries and has served approximately 75,000 people.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.2: Reduce Under-5 Mortality
- 3.4: NCDs (including mental health)
- 3.C: Health workforce
SDG 5: Gender Equality
SDG 9: Industry Innovation and Infrastructure
SDG 10: Reduced Inequalities
SDG 17: Partnerships for the Goals
RESULTS & MILESTONES
In 2017 a new patient-centered access model, CMLPath to Care™, replaced GIPAP. Under the new initiative, The Max Foundation assumes from Novartis the responsibility for delivering treatment to these patients, including supply chain management. Novartis provides funding and drug donation support.
- South Africa
- Viet Nam
- Mental & Neurological Disorders
- Cardiovascular Diseases
- Respiratory Diseases
- General Noncommunicable Disease Care (Health System)
- Other NCD
- Gastrintestinal Stromal Tumour